Phase II evaluation of mitoxantrone in advanced non anaplastic thyroid cancer.
Sixteen evaluable patients with non anaplastic thyroid carcinoma were treated with mitoxantrone (16 mg/m2). There was only one brief partial remission (6.3%). There was noticeable toxicity. Mitoxantrone as given in this study was not effective for this patient population.
Schlumberger
M
M
Institut Gustave-Roussy, Rue Camille Desmoulins, Villejuif, France.
Parmentier
C
C
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D013964:Thyroid Neoplasms / Q000188:drug therapy*
D008942:Mitoxantrone